Gonorrhea - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gonorrhea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gonorrhea - Pipeline Review, H2 2014', provides an overview of the Gonorrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gonorrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gonorrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gonorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gonorrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gonorrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gonorrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gonorrhea Overview 6
Therapeutics Development 7
Pipeline Products for Gonorrhea - Overview 7
Pipeline Products for Gonorrhea - Comparative Analysis 8
Gonorrhea - Therapeutics under Development by Companies 9
Gonorrhea - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Gonorrhea - Products under Development by Companies 12
Gonorrhea - Companies Involved in Therapeutics Development 13
Melinta Therapeutics, Inc 13
Cubist Pharmaceuticals, Inc. 14
PTC Therapeutics, Inc. 15
Genocea Biosciences, Inc. 16
Gonorrhea - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
delafloxacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
solithromycin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gonorrhea Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PTC-672 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
edodekin alfa SR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gonorrhea - Recent Pipeline Updates 35
Gonorrhea - Dormant Projects 46
Gonorrhea - Product Development Milestones 47
Featured News & Press Releases 47
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 47
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin`s Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 47
Sep 06, 2014: Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program 48
Sep 04, 2014: Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting 48
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 49
Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID 50
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Gonorrhea, H2 2014 7
Number of Products under Development for Gonorrhea - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Gonorrhea - Pipeline by Melinta Therapeutics, Inc, H2 2014 13
Gonorrhea - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 14
Gonorrhea - Pipeline by PTC Therapeutics, Inc., H2 2014 15
Gonorrhea - Pipeline by Genocea Biosciences, Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Gonorrhea Therapeutics - Recent Pipeline Updates, H2 2014 35
Gonorrhea - Dormant Projects, H2 2014 46